April Palmer
Family Medicine · Shreveport, LANPI 1104830306
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,053 and has fallen 99.3% since, to $15 in 2024.
Across 440 payments — averaging $13.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$574
- Merck$528
- AstraZeneca$522
- Takeda Pharmaceuticals U.S.A., Inc.$418
- Novo Nordisk$406
- plus $2K from 25 others
Across 2 payments — averaging $750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$2K
What the payments were for
- Food & beverage$6,133100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $1,218 |
| Lilly USA, LLC | 43 | $574 |
| Merck | 30 | $528 |
| AstraZeneca(2 entities) | 38 | $522 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $418 |
| Novo Nordisk | 27 | $406 |
| Boehringer Ingelheim | 27 | $382 |
| Amgen | 18 | $296 |
| Johnson & Johnson | 14 | $206 |
| Pfizer | 13 | $202 |
| Amarin Pharma, Inc. | 10 | $176 |
| Sanofi-aventis U.S. LLC | 10 | $137 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $131 |
| Biohaven Pharmaceuticals, Inc. | 8 | $120 |
| Daiichi Sankyo Inc. | 5 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $104 |
| Kowa Pharmaceuticals America, Inc. | 7 | $103 |
| Teva Pharmaceuticals USA, Inc. | 7 | $94 |
| GSK | 5 | $75 |
| Abbott | 5 | $71 |
| Ironshore Pharmaceuticals Inc. | 3 | $47 |
| Upsher-smith Laboratories LLC | 3 | $46 |
| Neos Therapeutics, LP | 2 | $31 |
| Eisai Inc. | 2 | $24 |
| IBSA Pharma Inc. | 1 | $24 |
| Corium, LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Tris Pharma Inc | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$118
How this compares
$6,142 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Shreveport
- Michael FlemingShreveport$165K
- Krishna SinghShreveport$22K
- Larry FlakeShreveport$20K
- Russell CarrShreveport$17K
- Richard KammShreveport$17K
- Wendy MosesShreveport$16K
- William GibsonShreveport$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Robert St AmantGonzales$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.